Navigation Links
AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles

rapeutic approaches that add to the breadth and depth of our product pipeline," said Dr Jurgen Engel, Executive Vice President, Global R&D and Chief Operating Officer at AEterna Zentaris. "The potential for cancer treatment with agents inhibiting the PI3K pathway has become a focus in recent drug discovery and development research. We believe that by developing novel selective PI3K inhibiting small molecular compounds, we are positioning ourselves as one of the leaders in this promising therapeutic approach."

Cellular substrate phosphorylation studies targeting the inhibition of PI3K and functional cellular assays of tumor cell proliferation have been performed. In addition, physicochemical and initial ADMET data were collected. Several derivatives are currently undergoing first pharmacokinetic in vivo studies.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aeternazentaris.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual res
'"/>




Page: 1 2 3

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
11. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial

Post Your Comments:
(Date:11/9/2009)...ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today...epreve(TM) (bepotastine besilate ophthalmic soluti...were presented in poster sessions at the 2009 Annu...hma & Immunology (ACAAI) in Miami Beach, FL. ...of Ocular Itching with Bepotastine Besilate Ophtha...
(Date:11/9/2009)...ll/ -- Arcadia Resources, Inc. (NYSE Amex: KAD ),...care services under the Arcadia HealthCare(SM) bra...f Directors. Goldsmith will replace Tres Lund who..., (Photo: http://www.newscom.com/cgi-bin/prnh/20...aul Professor of Government and Director of Innova...
(Date:11/9/2009)...ia/ -- Chindex International, Inc.,("Chindex") (Na...ider of Western,healthcare products and services i...results for the second quarter and first half of f... Financial Highlights:, -- Revenue in the seco...on, a year over year basis;, -- Net incom...
Breaking Medicine Technology:ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 2Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 4Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 5Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 6Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 7Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 8Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 9Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 10Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 11Study of agricultural watersheds and carbon losses 8933 1Study of agricultural watersheds and carbon losses 8933 2Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution 8931 1Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution 8931 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 1Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 2Children 26apos 3Bs National Medical Center Dedicates New Blood Donor Center 49506 3
... ASCO Cancer Conference, NORTH HOLLYWOOD, Calif., ...ernational Myeloma Foundation (IMF)-supporting res...t for myeloma patients,families, researchers and ...o a Phase 3 multi- national clinical trial shows t...s the probability of,survival by 41%. The follow-u...
...June 05, 2007 /PRNewswire-FirstCall/ --,Nuvelo, In...preclinical study of novel monoclonal antibodies a...monstrate that NTB-A is a,potential new target for...ukemia and lymphomas. The study, entitled "The lym...nal antibody target for,leukemia and lymphoma ther...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas 2Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas 3Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas 4
(Date:11/9/2009)...e funds to move lab findings into human therapy fo...from nerve damage ,, ANN ARBOR, Mich., Nov. 9 ...versity of Michigan Department of Neurology have r...erapy for neuropathic pain, a difficult-to-treat c... of damage to nerve without obvious tissue injury....
(Date:11/9/2009)...e in French . , , Montreal, November 9, 2009...ale. In human bodies trillions of cells are couple...re composed. Yet these don,t come in twos, they a...use these complex cell networks are the backbone o... for ways to splice cell clusters down to their or...
(Date:11/9/2009)... 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the gl...nounced the availability of INTUNIV (guanfacine) E...nited States for the treatment of Attention-Defici...olescents ages 6 to 17. INTUNIV, a once-daily for...cheduled alpha-2A receptor agonist approved for th...
(Date:11/9/2009)...ple around the world suffer from cataracts. Thomas...his coauthors discuss cataract surgery with the im...sue of Deutsches rzteblatt International ( Dtsch...ndness is usually due to opacification of the lens...rations are performed each year. Cataracts can be ...
(Date:11/9/2009)... people have tried to read Charles Darwin,s "Origi...0th anniversary this month, but gave up. , For t...k is about, help by way of a new book is at hand. ...eznick is the author of "The Origin Then and N...s " (Princeton University Press, 2009), which mak...
Breaking Medicine News(10 mins):Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4Health News:Book by UC Riverside biologist explains Darwin's 'Origin of Species' 2
...disorders among adolescent girls and boys can have...ead to dangerous weight-control behaviors, such as...t pills to control weight. The middle school age i... at the Harvard School of Public Health (HSPH) set...
...d number of youth with office visits with a diagno...tween 1994 and 2003, while adult visits with a bip... according to a report in the September issue of A...a (an abnormally elevated mood) and depression. Al...
... "Psoriasis Cure,Now," a nonprofit patient advoca... parents of children with psoriasis as their kids ...e fact sheet on children,s psoriasis,that parents ...discussing how to treat psoriasis in children and ...
...er 3 KFH has announced that it,has succeeded in o...SO,9001:2000 quality management systems with the B... Director, Dr Sally Sennitt, MD, says: "We are del...d,one that very few young medical device companies...
... data about the safety of drug-,eluting stents (DE...,patients with cardiovascular disease, according t...nterventions (SCAI). These new findings,also under...gimen of medications that prevent blood clots in t...
...fforts to control population growth in the present...s in the future. , This prediction comes from a S...r who spent a year in China studying its geriatric...niversity, said Chinas 1979 policy of limiting cou...
Other Medicine News:Health News:School-based overweight prevention program may cut risk of eating disorders among girls 2Health News:Study documents rapid increase in youth bipolar disorder diagnoses 2Health News:Psoriasis Cure Now offers 'Back to School' Resources for Parents of Children with Psoriasis 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 3Health News:China's 1-child policy could backfire on its elderly 2Health News:China's 1-child policy could backfire on its elderly 3
Osmetech OPTI CCA Touch
IRMA TRUPOINT Blood Analysis System
Horizon Series Platelet Agitator PF48h
...tors offer a wide range of storage capacities. Del...atform to agitate smoothly, eliminating the need f...y, one-piece perforated drawers with non-slip text...our platelets., ,i.Series platelet agitators f...
Medicine Products: